Switching to iGlarLixi vs Continuation of Glucagon-Like Peptide-1 Receptor Agonist in Inadequately Controlled Type 2 Diabetes Mellitus: The Randomised LixiLan-G Trial - Poster
Lawrence Blonde1, Julio Rosenstock2, Stefano Del Prato3, Robert Henry4, Naim Shehadeh5, Juan Frias6, Elisabeth Niemoeller7, Elisabeth Souhami8, Junlong Wu9, Chen Ji9, Vanita R. Aroda10